“””Lyell Immunopharma, a clinical-stage biotech firm, is leading the charge in the development of innovative CAR T-cell therapies for hematologic malignancies and solid tumors. By integrating a robust spectrum of technologies, Lyell refines CAR T cells to ensure they remain cytotoxic to tumors, facilitate lasting clinical responses, resist exhaustion, retain stemness qualities, and operate effectively […]